24 June 2026

# Osteopore's neurosurgery products approved for use in a major medical centre in Thailand

## Highlights

- **Osteopore is delighted to announce that its neurosurgery products have been approved for use in a major medical centre in Bangkok, Thailand – Thammasat University Hospital.**
- **This positive development follows the appointment of Peakmed Co., Ltd (Peakmed) as Osteopore's exclusive distributor in Thailand, as announced on 6 May 2025[1].**

Australian-Singaporean regenerative medicine company **Osteopore Limited** (**ASX: OSX**; **Osteopore** or **the Company**) – a global leader in 3D-printed biomimetic and bioresorbable implants – is delighted to announce the approval of its neurosurgery products in a major medical centre in Bangkok, Thailand.

This positive development follows the appointment of Peakmed Co., Ltd (Peakmed) as Osteopore's exclusive distributor in Thailand, as announced on 6 May 2025[1]. The centre where Osteopore's products have been approved is Thammasat University Hospital.

Thammasat University Hospital (TUH) is a teaching hospital with more than 1,500 outpatients a day and has more than 800 beds for inpatient care[2]. TUH a high-level tertiary care hospital

[1] ASX announcement, "Osteopore strengthens Thailand craniofacial distribution", 6 May 2025.

[2] https://en.wikipedia.org/wiki/Thammasat_University_Hospital

and referral centre serving Pathum Thani, Bangkok, and the wider central region of Thailand. Established by royal decree and granted Advanced Healthcare Accreditation by Thailand's Healthcare Accreditation Institute, the hospital accommodates an average of 4,000 outpatient visits per day and currently operates more than 800 inpatient beds, with capacity expanding toward 1,000 beds as part of its transition into a Super Tertiary University Hospital and hub of specialised Centres of Excellence[3].

As the teaching hospital of Thammasat University's Faculty of Medicine, it trains specialists across all major disciplines, including a dedicated neurosurgery division accredited by the Royal College of Neurological Surgeons of Thailand.

Adoption within the Department of Surgery's neurosurgery division was supported by Dr Vich Yindeedej[4], a Thammasat-trained neurosurgeon with international fellowships in epilepsy, functional, and paediatric neurosurgery from Osaka Metropolitan University and Osaka City General Hospital, Japan.

This combination of institutional scale, clinical accreditation, and specialist expertise provides a strong foundation for the broader adoption of Osteopore's technology within one of Thailand's leading academic medical centres.

Based on published data sourced from Thailand's National Health Security Office (NHSO), 93,810 brain tumour patients were admitted over 10 years (2005 to 2014).[5]

As one of the Company's more mature product lines, Osteopore's neurosurgical implants are focused on treating a range of brain surgeries where bone tissue is removed, such as burr hole and craniotomy procedures.

---

[3] https://www.hospital.tu.ac.th/en/page/about-hospital/

[4] https://www.med.tu.ac.th/department/surgery/staff/

[5] J Med Assoc Thai Vol. 99 Suppl. 3 2016

Thailand's craniomaxillofacial (CMF) market is a primary focus for Osteopore due to the significant number of neurosurgical procedures. Neurosurgery is a one segment within the broader CMF market.

According to a report published by the Thailand Board of Investment[6] Thailand's medical device market has a trade value of US$19.93 billion, while its import value was US$5.99 billion in 2020, ranking Thailand second only to Singapore (US$ 9.94 billion).

**ENDS**

*This announcement has been authorised for release to the ASX by the Board of Osteopore Limited*.

For more information, please contact:

**Dr Yujing Lim**
Chief Executive Officer
Osteopore Limited
E: lim_yujing@osteopore.com

**Mark Leong**
Executive Chairman
Osteopore Limited
E: mark_leong@osteopore.com

### About Osteopore Limited

Osteopore Ltd. is a global medical technology company founded in Singapore and listed in Australia that commercialises products designed to enable natural bone healing across multiple therapeutic areas. Osteopore's patented technology fabricates specific micro-structured scaffolds for bone regeneration through 3D printing and bioresorbable material.

Osteopore's patent-protected scaffolds are manufactured using a proprietary manufacturing technique with a polymer that naturally dissolves over time to only allow natural and healthy bone

[6] https://www.boi.go.th/upload/content/Infopack_MedDevice.pdf

tissue, significantly reducing the post-surgery complications commonly associated with permanent bone implants. Our 3D printing technology is unique to Osteopore.

**Forward-Looking Statements**

Some of the statements appearing in this announcement may be similar to forward-looking statements. You should be aware that such statements are only predictions and are subject to inherent risks and uncertainties. Those risks and uncertainties include factors and risks specific to the industries in which the Company operates and proposes to operate as well as general economic conditions, prevailing exchange rates and interest rates and conditions in the financial markets, among other things.

Actual events or results may differ materially from the events or results expressed or implied in any forward-looking statement. No forward-looking statement is a guarantee or representation as to future performance or any other future matters, which will be influenced by several factors and subject to various uncertainties and contingencies, many of which will be outside the Company's control. The Company does not undertake any obligation to update publicly or release any revisions to these forward-looking statements to reflect events or circumstances after today's date or to reflect the occurrence of unanticipated events.

No representation or warranty, express or implied, is made as to the fairness, accuracy, completeness or correctness of the information, opinions or conclusions contained in this announcement. To the maximum extent permitted by law, neither of the Company's Directors, employees, advisors or agents, nor any other person, accepts any liability for any loss arising from the use of the information contained in this announcement.

You are cautioned not to place undue reliance on any forward-looking statement. The forward-looking statements in this announcement reflect views held only as at the date of this announcement. This announcement is not an offer, invitation or recommendation to subscribe for or purchase securities by the Company. Nor does this announcement constitute investment or financial product advice (nor tax, accounting or legal advice) and is not intended to be used for the basis of making an investment decision. Investors should obtain their own advice before making any investment decision.